Frontlight ResearchEarly access
WithdrawnPhase 3
Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction
Key facts
- Who runs it
- Vastra Gotaland Region
- Trial code
- Status
- Withdrawn
- Phase
- Phase 3
- Started
- 1 Jan 2023
- Ended
- Dec 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- Adenosine
- Record updated
- 17 May 2024
- Why it stopped
- Never started
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Age >18 years
- Anterior STEMI
- Symptom duration ≤6 hours
- Written informed consent obtained - Angiographic Inclusion criteria:; Culprit lesion in LAD, major branch of LAD, proximal or mid LCx or proximal or mid RCA; TIMI flow ≤2 in the culprit vessel; -Echocardiographic inclusion criteria:; Detectable hypo- or akinesia corresponding to ≥5% of the left ventricle corresponding to culprit lesion, per bedside visual assessment
Who cannot take part
- Previous randomization in the study
- Any of the following contraindications for treatment with adenosine:; Known pre-existing atrioventricular block grade ≥2 or sick sinus syndrome in patients without pacemaker; Known pre-existing elevation of intracranial pressure; Treatment with dipyridamole within 24 hours of randomization; Systolic blood pressure <80 mm Hg at screening
- Any concomitant condition resulting in a life expectancy of less than one month
- Previous myocardial infarction or other cardiac condition resulting in impaired regional or global systolic function without documented recovery of cardiac function
- Heart transplant or left ventricular assist device recipient
- Not suitable in the opinion of the investigator due to severe or terminal comorbidity with poor prognosis or characteristics that may interfere with adherence to the trial protocol
- Pregnancy or woman of childbearing potential who is not sterilized or using a medically accepted form of contraception -
About the trial
What the trial wants to find out
The aim of this study is to evaluate the effect of adenosine on the recovery of myocardial akinesia in ST-elevation myocardial infarction (STEMI). The study is a single-center randomized clinical trial intending to include 90 patients.
Read full original descriptionShow less
The objective of the study is to investigate whether treatment with adenosine hastens recovery of myocardial akinesia and improves cardiac function at 48 hours in patients with STEMI.
The 2 groups in the trial
- AdenosineTreatment being tested
Adenosine infusion 70 µg/kg/min initiated prior to revascularization and maintained for 6 hours
- ControllNo study treatment, for comparison
Standard of care
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction An Open-label, Single Center Trial
- Record updated
- 17 May 2024